NCT02942758终止2 期
Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- overall Survival
研究概览
简要总结
Diagnosis: Acute myeloid leukemia refractory to intensive induction chemotherapy; Age ≥ 60 years, no upper age limit; Study drug: low-dose azacitidine, pioglitazone, ATRA; Safety Run-In Phase; randomized Phase II, open-label
- Safety Run-In Phase: Based on a 3 + 3 modified design, the tolerable dose of ATRA for the randomized phase II is defined.
- Phase II: Experimental Arm: low-dose azacitidine, pioglitazone, ATRA; Standard Arm: standard-dose azacitidine; in both arms patients can receive further cycles (with no limit to the number given) as long as clinically appropriate
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with confirmed diagnosis of acute myeloid leukemia (AML) who are refractory* to induction therapy and not eligible for further intensive induction therapy based on documented medical reasons (e.g. disease characteristics or patient characteristics), or
- •Patients with confirmed diagnosis of acute myeloid leukemia (AML) who are refractory* to induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
- •*refractory to induction therapy is defined as no CR, no CRi and no PR (according to standard criteria, see Section 11.2.3) after at least one intensive induction therapy including at least 5 days of cytarabine 100-200 mg/m² continuously or an equivalent regimen with cytarabine with total dose not less than 500 mg/m² per cycle and at least 2 days of an anthracycline (e.g. daunorubicin, idarubicin).
- •Age ≥ 60; no upper age limit
- •ECOG performance status of ≤ 2 at screening
- •To control hyperleukocytosis or extramedullary involvement, medication with hydroxyurea is allowed up to 24h before start of study treatment. In case of hyperleukocytosis hydroxyurea should be given and start of study treatment should be delayed until leukocyte counts are < 20 x 10^9/L.
- •Female subjects of childbearing potential* may participate, providing they meet the following conditions:
- •Have a negative pregnancy test (serum or urine with a sensitivity of at least 25 mIU/mL; local laboratory) within 72 hours prior to starting study therapy. They must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices true abstinence** from heterosexual contact.
- •Agree to practice true abstinence** from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with two effective methods of contraception (e.g., oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption during the study therapy (including dose interruptions), and for 3 months after discontinuation of study drugs.
- •A female subject of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
- •True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Male patients with a female partner of childbearing potential must agree to abstain from sexual intercourse or to the use of at least two effective contraceptive methods (e.g., synthetic condoms with spermicide, etc) at screening and throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last study treatment.
- •Signed written informed consent.
排除标准
- •Known or suspected hypersensitivity to the study drugs and/or any excipients
- •Patients with acute promyelocytic leukemia exhibiting t(15;17)(q22;q12); PML-RARA, or with variant translocations
- •Acute myeloid leukemia (AML) with isocitratdehydrogenase (IDH) 1 or 2 mutations if results are available from the central AMLSG reference laboratories
- •ECOG performance status > 2
- •Inadequate cardiac, hepatic and/or renal function at Screening Visit defined as:
- •heart failure NYHA II-IV
- •unstable angina pectoris
- •total bilirubin, ALT, AST > 2.5 x upper normal serum level
- •Creatinine > 1.5 x upper normal serum level
- •Active central nervous system involvement
- •Uncontrolled infection
- •Uncontrolled diabetes mellitus
- •Patients with a "currently active" second malignancy requiring active therapy other than non-melanoma skin cancers (except for hormonal/antihormonal treatment, e.g. in prostate or breast cancer)
- •Patients with "currently active" bladder cancer or bladder cancer in their history, patients with risk factors for bladder cancer (e.g. exposure to aromatic amines or heavy tobacco smoker), or macrohematuria of unknown origin
- •Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
- •Known or suspected active alcohol or drug abuse
- •Known positive for HIV, active HBV or HCV infection
- •No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
- •Treatment with any other clinical study drug within 14 days before the first administration of the investigational drugs or at any time during the study
- •Breast feeding woman or women with a positive pregnancy test at Screening Visit
- •Male patients with a female partner of childbearing potential not willing to abstain from sexual intercourse or to the use of at least two effective contraceptive methods (e.g., synthetic condoms with spermicide, etc) at screening and throughout the course of the study and for 3 months following the last study treatment.
研究组 & 干预措施
low-dose AZA / ATRA / Pioglitazone
Experimental
low-dose azacitidine (75 mg/d), ATRA, pioglitazone
干预措施: low-dose Azacitidine (Drug)
low-dose AZA / ATRA / Pioglitazone
Experimental
low-dose azacitidine (75 mg/d), ATRA, pioglitazone
干预措施: Pioglitazone (Drug)
low-dose AZA / ATRA / Pioglitazone
Experimental
low-dose azacitidine (75 mg/d), ATRA, pioglitazone
干预措施: ATRA (Drug)
standard-dose AZA
Active Comparator
standard-dose azacitidine (75mg/m²/d)
干预措施: standard-dose AZA (Drug)
结局指标
主要结局
overall Survival
时间窗: 3 years
次要结局
- cumulative incidence of death (CID)(3 years)
- event free survival (EFS)(3 years)
- cumulative incidence of relapse (CIR)(3 years)
- complete remission with incomplete blood count recovery (CRi) rate(3 years)
- complete remission (CR) rate(3 years)
- partial remission (PR) rate(3 years)
- hematological improvement (HI) rate(3 years)
- Quality of Life (QLQ-C30)(3 years)
- cumulative incidence of relapse event free survival (EFS)(3 years)
- Incidence and intensity of adverse events (AEs)(3 years)
研究者
Simone Thomas
Dr. med.
University Hospital Regensburg
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)NCT04275518Ascentage Pharma Group Inc.102
终止
1 期
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT06068868AbbVie36
已完成
2 期
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageAllogeneic Hematopoietic Stem Cell Transplant RecipientBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlastic Plasmacytoid Dendritic Cell NeoplasmChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionDonorLymphoblastic LymphomaMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome With Excess Blasts-2Recurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionAcute Undifferentiated LeukemiaNCT02220985Fred Hutchinson Cancer Center84
已完成
2 期
Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With ChemotherapyNon-Small Cell Lung CancerNCT00489983Eli Lilly and Company91
进行中（未招募）
3 期
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeDown SyndromeMyeloid Leukemia Associated With Down SyndromeMyeloproliferative NeoplasmAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02521493Children's Oncology Group280